Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 12-Month High – Here’s Why

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) reached a new 52-week high during trading on Tuesday . The company traded as high as $15.15 and last traded at $15.1920, with a volume of 32705 shares trading hands. The stock had previously closed at $14.82.

Wall Street Analysts Forecast Growth

AMRX has been the topic of a number of recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $13.00 price target (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Truist Financial set a $15.00 price target on Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Barclays initiated coverage on shares of Amneal Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $15.00 price target on the stock. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.80.

Amneal Pharmaceuticals Stock Down 0.9%

The firm has a market cap of $4.63 billion, a price-to-earnings ratio of 735.07 and a beta of 1.36. The company has a 50 day moving average of $13.45 and a 200 day moving average of $11.45.

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Kemnay Advisory Services Inc. bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $26,000. Federated Hermes Inc. raised its holdings in shares of Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares during the period. Comerica Bank boosted its stake in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the period. Exchange Traded Concepts LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth approximately $31,000. Finally, Spire Wealth Management grew its stake in Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.